The estimated Net Worth of Casey C. Kopczynski is at least 11.8 百万$ dollars as of 15 February 2021. Casey Kopczynski owns over 60,651 units of Aerie Pharmaceuticals Inc stock worth over 4,049,211$ and over the last 11 years he sold AERI stock worth over 5,770,730$. In addition, he makes 1,965,910$ as Co-Founder、 Chief Scientific Officer at Aerie Pharmaceuticals Inc.
Casey has made over 13 trades of the Aerie Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 60,651 units of AERI stock worth 12,130$ on 15 February 2021.
The largest trade he's ever made was exercising 117,000 units of Aerie Pharmaceuticals Inc stock on 3 December 2019 worth over 47,970$. On average, Casey trades about 9,677 units every 34 days since 2013. As of 15 February 2021 he still owns at least 265,522 units of Aerie Pharmaceuticals Inc stock.
You can see the complete history of Casey Kopczynski stock trades at the bottom of the page.
DR. Casey C. Kopczynski Ph.D. serves as Co-Founder, Chief Scientific Officer of the Company. From 2002 to 2005, Dr. Kopczynski was the Managing Partner at Biotech Initiative, LLC, a consulting practice dedicated to emerging biotech companies. Dr. Kopczynski was also previously the Vice President of Research at Ercole Biotech, Inc. from 2003 to 2004, a company developing drugs for the treatment of cancer, inflammation and orphan genetic diseases. Prior to Ercole Biotech, Inc., Dr. Kopczynski was Director of Research and a founding member of the scientific staff at Exelixis, Inc. from 1996 to 2002. Dr. Kopczynski received his Ph.D. in Molecular, Cellular and Developmental Biology from Indiana University and was a Jane Coffin Childs Research Fellow at the University of California, Berkeley.q
As the Co-Founder、 Chief Scientific Officer of Aerie Pharmaceuticals Inc, the total compensation of Casey Kopczynski at Aerie Pharmaceuticals Inc is 1,965,910$. There are 4 executives at Aerie Pharmaceuticals Inc getting paid more, with Vicente Anido having the highest compensation of 5,529,670$.
Casey Kopczynski is 58, he's been the Co-Founder、 Chief Scientific Officer of Aerie Pharmaceuticals Inc since 2005. There are 13 older and 8 younger executives at Aerie Pharmaceuticals Inc. The oldest executive at Aerie Pharmaceuticals Inc is Gerald Cagle, 75, who is the Independent Director.
Casey's mailing address filed with the SEC is C/O AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM, NC, 27703.
Over the last 11 years, insiders at Aerie Pharmaceuticals Inc have traded over 194,685,628$ worth of Aerie Pharmaceuticals Inc stock and bought 2,240,245 units worth 39,233,665$ . The most active insiders traders include Group Holdings (Sbs) Adviso...、Anand Mehra、Capital Management Ii, Llc .... On average, Aerie Pharmaceuticals Inc executives and independent directors trade stock every 45 days with the average trade being worth of 2,718,618$. The most recent stock trade was executed by Casey C. Kopczynski on 15 February 2021, trading 60,651 units of AERI stock currently worth 12,130$.
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema.
Aerie Pharmaceuticals Inc executives and other stock owners filed with the SEC include: